Drug-resistant tuberculosis: Worldwide trends, problems specific to Eastern Europe and other hotspots, and the threat to developing countries

Current Opinion in Pulmonary Medicine

Volumn 7, Issue 3, 2001, Pages 148-153

  Willcox, Paul A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

DEVELOPING COUNTRY; DRUG EFFECT; EASTERN EUROPE; ERADICATION THERAPY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION CONTROL; MULTIDRUG RESISTANCE; PRESCRIPTION; PREVALENCE; REVIEW; TUBERCULOSIS;

EID: 0035012287     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200105000-00006     Document Type: Review

References (31)

1. 1 Fox W, Ellard GA, Mitchison DA: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant independent publications. Int J Tuberc Lung Dis 1999, 3:S231-S279. An excellent reference on the many studies performed by the British Medical Research Council Tuberculosis Units.
2. 2 Raviglione MC, Dye C, Schmidt S, et al.: Assessment of worldwide tuberculosis control, Lancet 1997, 350:624-629.
3. 3 World Health Organization: WHO declares tuberculosis a global emergency. Geneva: World Health Organization; 1993. [WHO publication no. 31.]
4. 4 Mitchison D, Nunn A: Influence of initial drug resistance on the response to short course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986, 133:423-430.
5. 5 Espinal MA, Kim SJ, Suarez PG, et al.: Standard short-course chemotherapy for drug resistance. Treatment outcomes in 6 countries. JAMA 2000, 283:2537-2545.
6. 6 Schatz A, Waksman SA: Effect of streptomycin and other antibiotic substances on Mycobacterium tuberculosis and related organisms. Proc Soc Exp Biol Med 1944, 57:244-248.
7. 7 Youmans GP: Increase of resistance of tubercle bacilli to streptomycin: a preliminary report. Proc Staff Meet Mayo Clin 1946, 21:126-127.
8. 8 Mitchison DA: Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis. Thorax 1950, 5:144-161.
9. 9 World Health Organisation: Anti-Tuberculosis Drug Resistance in the World. The WHO/IUATLD global project on antituberoulous drug resistance surveillance 1994-1997. WHO/TB/97.229. Geneva, World Health Organisation, 1997.
10. 10 Goble M, Iseman MD, Madsen LA, et al.: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. N Engl J Med 1993, 328:527-532.
11. 11 Pablos-Mendez A, Raviglione MC, Laszlo A, et al.: Global surveillance for antituberculous drug resistance, 1994-1997. N Engl J Med 1998, 338:1641-1649.
12. 12 The WHO/IUATLD Global Project on Anti-Tuberculous Drug Resistance Surveillance: Anti-Tuberculous Drug Resistance in the World: Report No 2. Prevalence and Trends, Geneva, World Health Organisation, 2000. This is the definitive publication on the global prevalence and trends on drug resistance. In this second report from the WHO/IUATLD global initiative, surveillance of drug resistance has been expanded to involve 75 countries and regions. For the first time, data on trends were available.
13. 13 van Rie A, Warren R, Richardson M, et al.: Classification of drug-resistant tuberculosis in an epidemic area. Lancet 2000, 356:22-25.
14. 14 Becerra MC, Bayona J, Freeman J, et al.: Redefining MDR-TB transmission "hot spots." Int J Tuberc Lung Dis 2000, 4:387-394. This paper takes data from the first WHO/IUATLD report on prevalence of drug resistance and analyzes it in a different way. The authors have calculated the absolute numbers of MDR-TB cases expected per annum in various countries. Based on this, they have re-defined MDR-TB hotspots as those countries that are estimated to have more than 500 oases par year.
15. 15 Portaels F, Rigouts L, Bastian I: Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999, 3:582-588.
16. 16 Holden C: Stalking a killer in Russia's prisons. Science 1999, 286:1670.
17. 17 Drobniewski F, Tayler E, Ignatenko N, et al.: Tuberculosis in Siberia: 2, Diagnosis, chemoprophylaxis and treatment. Tuberc Lung Dis 1996, 77:297-301.
18. 18 Tanne JH: Drug resistant TB is spreading worldwide. Br Med J 1999, 319:1220.
19. 19 Connix R, Pfyffer GE, Mathieu C, et al.: Drug resistant tuberculosis in prisons in Azerbaijan: case study. Br Med J 1998, 3116:1423-1425.
20. 20 Kimerling ME, Kluge H, Vezhnina N, et al.: Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999, 3:451-453.
21. 21 Banatvala N, Matic S, Kimerling M, et al.: Letter, Lancet 1999, 354:1036.
22. 22 Dye C, Scheele S, Dolin P, et al., for the Global Surveillance and Monitoring Project; Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. JAMA 1999, 282:677-686.
23. 23 Kuaban C, Bercion R, Noeske J, et al.: Anti-tuberculous drug resistance in the West Province of Cameroon. Int J Tuberc Lung Dis 2000, 4:356-360.
24. 24 Kuaban C, Bercion R, Jifon G, et al.: Acquired anti-tuberculous drug resistance in Yaounde, Cameroon. Int J Tuberc Lung Dis 2000, 4:427-432.
25. 25 Davies GR, Pillay M, Sturm AW, et al.: Emergence of multidrug-resistant tuberculosis in a community-based directly observed treatment program in rural South Africa. Int J Tuberc Lung Dis 1999, 3:799-804.
26. 26 Garcia-Garcia M de L, Ponce-de-Leon A, Jimenez-Corona ME et al.: Clinical consequences and transmissibility of drug-resistant tuberculosis in Southern Mexico. Arch Intern Med 2000, 160:630-636.
27. 27 Granich RM, Balandrano S, Santaella AJ, et al.: Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican States, 1997. Arch Intern Med 2000, 160:639-644.
28. 28 Enarson DA: Resistance to antituberculous medications. Hard lessons to learn. Arch Intern Med 2000, 160:581-582.
29. 29 Heymann SJ, Brewer TF, Wilson ME, et al.: The need for global action against multidrug-resistant tuberculosis. JAMA 1999, 281:2138-2140.
30. 30 Sosna J, Shulimzon T, Roznman J, et al.: Drug-resistant pulmonary tuberculosis in Israel, a society of immigrants: 1985-1994. Int J Tuberc Lung Dis 1999, 3:689-694.
31. 31 Kenyon TA, Mwasekaga MJ, Huebner R, et al.: Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999, 3:4-11. An example of how DOTS may help to control drug-resistant tuberculosis during an HIV and tuberculosis co-epidemic.